Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancer.

ABSTRACT:

Background

In colorectal cancer, inappropriate use of adjuvant chemotherapies may lead to significant increases in healthcare costs and harms to patients. Genome-based interventions are being increasingly used in the stratification of patients according to their risk profiles. However, earlier cost-effectiveness analyses of precision molecular diagnostics have indicated a paucity of data on comparative health economic outcomes. Our aim was to compare the cost-effectiveness of marketed genomic tests used in the prognosis of stage II colorectal cancer patients.

Methods

A Markov model was developed to compare the cost-effectiveness of treatment guided by any one of the following genomic tests: 12-gene assay or the 18-gene expression assay or the 482-gene signature or the Immuno

SUBMITTER: Chaudhari VS 

PROVIDER: S-EPMC9816824 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature